345 related articles for article (PubMed ID: 16670247)
1. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
van Dyck CH; Schmitt FA; Olin JT;
Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
[TBL] [Abstract][Full Text] [Related]
2. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
3. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
4. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
[TBL] [Abstract][Full Text] [Related]
6. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
7. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
[TBL] [Abstract][Full Text] [Related]
8. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
10. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
[TBL] [Abstract][Full Text] [Related]
11. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
15. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Jones R; Sheehan B; Phillips P; Juszczak E; Adams J; Baldwin A; Ballard C; Banerjee S; Barber B; Bentham P; Brown R; Burns A; Dening T; Findlay D; Gray R; Griffin M; Holmes C; Hughes A; Jacoby R; Johnson T; Jones R; Knapp M; Lindesay J; McKeith I; McShane R; Macharouthu A; O'Brien J; Onions C; Passmore P; Raftery J; Ritchie C; Howard R;
Trials; 2009 Jul; 10():57. PubMed ID: 19630974
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
[TBL] [Abstract][Full Text] [Related]
17. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
18. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
19. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
20. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
